Rehabtronics to Join PressureSmart Consortium for Advancing Pressure Injury Prevention Using Artificial Intelligence (AI)

Rehabtronics, a leader in advancing neurostimulation technology, is joining the PressureSmart Consortium in collaboration with six leading partners — Medtronic, Swift Medical, Thrive Health, Amii (Alberta Machine Intelligence Institute), Excelar, and Providence Health Care Ventures. This innovative project, co-funded by DIGITAL, Canada’s Global Innovation Cluster for digital technologies, aims to revolutionize the prevention, early detection, and management of pressure injuries (PIs).

Pressure injuries, which affect 26% of patients in Canadian healthcare settings, significantly diminish the patient’s quality of life and lead to costly, extended hospital stays. Rehabtronics’ proprietary technology Prelivia is designed to protect patients from pressure injuries by stimulating blood circulation, thereby increasing tissue oxygenation, and decreasing pressure induced tissue damage.

“We are pleased to collaborate with leading experts in advancing our mission to transform pressure injury care’ states Rahul Samant, CEO of Rehabtronics. “The integration of our Prelivia technology into the PressureSmart platform provides a cost-effective intervention for patients at risk or showing early signs of pressure injuries. Partnering with other technology leaders also allows us to leverage our combined strengths and deliver a scalable, comprehensive solution for managing pressure injuries.”

In addition to its Prelivia early intervention technology, Rehabtronics will develop an AI/ML (Artificial Intelligence/Machine Learning) model for the prediction of new and progressing hospital-acquired pressure injuries. This will enable nursing resources to be focused on the patients most in need.

“AI will revolutionize global health care systems by providing greater access and better outcomes for Canadians and for people around the world,” says Sue Paish, CEO of DIGITAL. “DIGITAL is proud to co-invest alongside Canadian innovators to support partnerships such as the PressureSmart project team to amplify Canadian industry expertise in building relevant AI solutions that advance human health while building global commercial pathways for Canadian companies.”

With a total budget of over 22 million, the PressureSmart project will enable clinicians and caregivers to track patient positioning, identify high-risk areas for PIs, and facilitate early intervention. This cohesive solution aims to enhance patient outcomes and quality of life, reduce clinical staff burden, and provide a scalable approach to address PI (Pressure Injuries) care.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.